The clinical success of Adcetris® (brentuximab vedotin) and Kadcyla® (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting in a relatively narrow therapeutic window. This review summarizes the therapeutic window of ADCs currently in clinical development, along with some strategies that may help to widen the window.
Citation: Bart ECG de Goeij1, John M Lambert New Developments For Antibody-drug Conjugate-based Therapeutic Approaches doi:10.1016/j.coi.2016.02.008
Available online: 7 March 2016
Copyright: ©2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflict of interest statement:
John M Lambert is an employee of ImmunoGen, Inc., the developer of the maytansinoid ADC platform utilized in ado-trastuzumab emtansine and in other ADCs in clinical development, and an ADC platform based on indolinobenzodiazepines. Bart ECG de Goeij is an employee of Genmab, the developer of HuMax-TF-ADC.